Terms: = Kidney tumors AND ARNT, HIF1BETA, 405, ENSG00000143437, P27540, HIF-1beta, HIF1B, TANGO
91 results:
1. Impact of adrenal surgeon volume on outcome: analysis of 4464 operations from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS).
Rajan S; Patel N; Stechman M; Balasubramanian SP; Mihai R; Aspinall S
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38306505
[TBL] [Abstract] [Full Text] [Related]
2. Computed tomography-based radiomics to assess risk stratification in pediatric malignant peripheral neuroblastic tumors.
Wang X; Wang X; Wu T; Hu L; Xu M; Tang J; Li X; Zhong Y
Medicine (Baltimore); 2023 Nov; 102(47):e35690. PubMed ID: 38013377
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy.
Sherry AD; Msaouel P; McCaw ZR; Abi Jaoude J; Hsu EJ; Kouzy R; Patel R; Yang Y; Lin TA; Taniguchi CM; Rödel C; Fokas E; Tang C; Fuller CD; Minsky B; Meirson T; Sun R; Ludmir EB
Eur J Cancer; 2023 Nov; 194():113357. PubMed ID: 37827064
[TBL] [Abstract] [Full Text] [Related]
4. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N; Govindarajan A; Zengin ZB; Meza L; Tripathi N; Sayegh N; Castro DV; Chan EH; Lee KO; Prajapati S; Feng M; Loo V; Pace M; O'Brien S; Bailey E; Barragan-Carrillo R; Chehrazi-Raffle A; Hsu J; Li X; Agarwal N; Pal SK
Clin Genitourin Cancer; 2023 Oct; 21(5):530-536. PubMed ID: 37495481
[TBL] [Abstract] [Full Text] [Related]
5. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract] [Full Text] [Related]
6. Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.
Yang X; Chai M; Xia L; He Z; Wu X; Zhang J
Acta Obstet Gynecol Scand; 2023 Jul; 102(7):950-959. PubMed ID: 37029431
[TBL] [Abstract] [Full Text] [Related]
7. Association between dietary 3-monochloropropane-1,2-diol esters (3-MCPDE) and renal cancer in Peninsular Malaysia: exposure assessment and matched case-control study.
Muhamad Rosli SH; Lau MS; Khalid T; Maarof SK; Jeyabalan S; Sirdar Ali S; Mustafa Khalid N; Md Noh MF; Salleh R; Palaniveloo L; Ahmad MH; Ahmad NI; Ahmad Suhaimi LR; Sharif Z; Abd Rahman N; Ahmad Bustamam RS; Malek R; Teoh BW; Khoo SC; Lim CS; Razali NH; Syed Mohamed AF
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2023 Apr; 40(4):475-492. PubMed ID: 36947708
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive Genomic Profiling of NF2-Mutated kidney tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract] [Full Text] [Related]
9. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.
Monteiro FSM; Soares A; Rizzo A; Santoni M; Mollica V; Grande E; Massari F
Clin Genitourin Cancer; 2023 Jun; 21(3):324-333. PubMed ID: 36823017
[TBL] [Abstract] [Full Text] [Related]
10. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
Lancet; 2023 Mar; 401(10379):821-832. PubMed ID: 36774933
[TBL] [Abstract] [Full Text] [Related]
11. Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma.
Lafleur VN; Halim S; Choudhry H; Ratcliffe PJ; Mole DR
Life Sci Alliance; 2023 Apr; 6(4):. PubMed ID: 36725335
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Follow-Up of Non-Enhancing Renal Masses on CEUS.
Barr RG; Cestone A; Peterson C; De Silvestri A
J Ultrasound Med; 2023 May; 42(5):963-968. PubMed ID: 36634009
[TBL] [Abstract] [Full Text] [Related]
13. Parathyroid carcinoma: Report of 10 patients and literature review.
Miao XY; Wang XL; Lyu ZH; Ba JM; Pei Y; Dou JT; Gu WJ; Du J; Guo QH; Chen K; Mu YM
Neuro Endocrinol Lett; 2022 Nov; 43(4):233-238. PubMed ID: 36528886
[TBL] [Abstract] [Full Text] [Related]
14. Minimally-Invasive Radical Nephrectomy and Left-Sided Level II Caval Thrombectomy: A New Combined Technique.
Zhang JH; Zeinab MA; Ferguson EL; Beksac AT; Schwen ZR; Aminsharifi A; Eltemamy M; Kaouk J
Urology; 2023 Feb; 172():220-223. PubMed ID: 36436673
[TBL] [Abstract] [Full Text] [Related]
15. Health effects of milk consumption: phenome-wide Mendelian randomization study.
Yuan S; Sun J; Lu Y; Xu F; Li D; Jiang F; Wan Z; Li X; Qin LQ; Larsson SC
BMC Med; 2022 Nov; 20(1):455. PubMed ID: 36424608
[TBL] [Abstract] [Full Text] [Related]
16. The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease.
Liu H; Li Y; Xiong J
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364144
[TBL] [Abstract] [Full Text] [Related]
17. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
18. THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.
Kaelin WG
Trans Am Clin Climatol Assoc; 2022; 132():170-181. PubMed ID: 36196173
[TBL] [Abstract] [Full Text] [Related]
19. Clinical and oncological outcomes of open partial nephrectomy versus robot assisted partial nephrectomy over 15 years.
Audigé V; Baghli A; Hubert J; Mazeaud C; Larré S; Branchu B
J Robot Surg; 2023 Apr; 17(2):519-526. PubMed ID: 35851947
[TBL] [Abstract] [Full Text] [Related]
20. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract] [Full Text] [Related]
[Next]
